



DOCKET NO.: ISIS-5213

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Phillip Dan Cook, et al.

Application No.: 10/601,242

Filing Date: June 20, 2003

For: GAPPED 2'-MODIFIED OLIGONUCLEOTIDES

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

DATE OF DEPOSIT: *July 24, 2003*

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Elizabeth A. McLoud

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date

of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith

EXCEPT THAT:


- ☒ In view of the voluminous nature of references 15, 16 and 25, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☒ Copies of references 1-81, 118-128 and 140-153 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **08/244,993**, filed **June 21, 1994** now U.S. Patent No. **5,623,065**; copies of references 82-90 and 129 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **08/861,306**, filed **April 21, 1997** now U.S. Patent No. **5,856,455**; copies of references 130-135 and 154 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **09/144,611**, filed **August 31, 1998** now U.S. Patent No.

6,146,829; copies of references 91-101, 136 and 155 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 09/453,514, filed **December 1, 1999** now U.S. Patent No. 6,326,199; copies of references 102-117, 137-139 and 156-160 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 09/951,052, filed **September 12, 2001**.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ There are no listed references which are not in the English language.

Date: July 24, 2003


Emma R. Dailey
Registration No. 48,491

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5213	Application No. 10/601,242
		Applicant Phillip Dan Cook, et al.	
		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	1	Agrawal, S. et al., "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus", <i>Proc. Natl. Acad. Sci. USA</i> , 1988 , 85, 7079-7083	
	2	Augustyns et. al., "Influence of the Incorporation of (S)-9-(3,4-dihydroxy-butyl)Adenine on the Enzymatic Stability and Base-Pairing Properties of Oligodeoxynucleotides", <i>Nucl. Acids Res.</i> , 1991 , 19, 2587-2593	
	3	Beaton et. al., Chapter 5, Synthesis of oligonucleotide phosphorodithioates, page 109, <i>Oligonucleotides and Analogs, A Practical Approach</i> , Eckstein, F. (Ed.), IRL Press, New York, 1991 , pp. 109-135	
	4	Borthwick et al., "Synthesis of Chiral Carbocyclic Nucleosides", <i>Tetrahedron</i> , 1992 , 48, 571-623	
	5	Brill et al., "Synthesis of Deoxydinucleoside Phosphorodithioates", <i>J. Am. Chem. Soc.</i> , 1991 , 113, 3972-3980	
	6	Cohen in <i>Oligonucleotides: Antisense Inhibitors of Gene Expression</i> , CRC Press, Inc., Boca Raton, FL (1989), 1-255	
	7	Cormier and Ogilvie, "Synthesis of Hexanucleotide Analogues Containing Diisopropylsilyl Internucleotide Linkages", <i>Nucl. Acids Res.</i> , 1988 , 16, 4583-4594	
	8	Dagle et al., "Physical properties of oligonucleotides containing phosphoramidate-modified internucleoside linkages", <i>Nucl. Acids Res.</i> , 1991 , 19, 1805-1810	
	9	Dagle et al., "Targeted degradation of mRNA in <i>Xenopus</i> oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis", <i>Nucl. Acids Res.</i> , 1990 , 18, 4751-4757	
	10	Dagle et al., "Pathways of Degradation and Mechanism of Action of Antisense Oligonucleotides in <i>Xenopus laevis</i> Embryos", <i>Antisense Research and Development</i> , 1991 , 1, 11-20	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5213	Application No. 10/601,242
		Applicant Phillip Dan Cook, et al.	
		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	11	Debart et al., "Intermolecular Radical C-C Bond Formation: Synthesis of a Novel Dinucleoside Linker for Non-anionic Antisense Oligonucleosides", <i>Tetra. Lett.</i> , 1992 , 33, 2645-2648	
	12	Eder, P.S. et al., "Ribonuclease H from K562 Human Erythroleukemia Cells", <i>J. Biol. Chem.</i> , 1991 , 266(10), 6472-6479	
	13	Gagnor et. al., "α-DNA VI: Comparative Study of α- and β-Anomeric Oligodeoxyribonucleotides in Hybridization to mRNA and in Cell Free Translation Inhibition", <i>Nucl. Acids Res.</i> , 1987 , 15, 10419-10436	
	14	Gait et al., "Synthetic Analogues of Polynucleotides. Part XII. Synthesis of Thymidine Derivatives Containing an Oxyacetamido- or and Oxyformamido-Linkage Instead of a Phosphodiester Group", <i>J.C.S Perkins I</i> , 1974 , 1684-1686	
*	15	Greenberg, M.E. in Current Protocols in Molecular Biology, Ausubel <i>et al.</i> (Eds.), John Wiley and Sons, NY	
*	16	Kawasaki et al., <i>Synthesis and Biophysical Studies of 2'-dRIBO-2'-F Modified Oligonucleotides</i> , Conference On Nucleic Acid Therapeutics, Clearwater, FL, January 13, 1991	
	17	Kawasaki et al., "Uniformly Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets", <i>J. Med. Chem.</i> , 1993 , 36, 831-841	
	18	Kierzek et. al., "Association of 2'-5' Oligoribonucleotides", <i>Nucl. Acids Res.</i> , 1992 , 20, 1685-1690	
	19	Kirshenbaum <i>et. al.</i> , <i>The 5th San Diego Conference: Nucleic Acids: New Frontiers</i> , Poster abstract 28, November 14-16, 1990	
	20	Matteucci et al., "Deoxyoligonucleotides Bearing Neutral Analogues of Phosphodiester Linkages Recognize Duplex DNA via Triple-Helix Formation", <i>J. Am. Chem. Soc.</i> , 1991 , 113, 7767-7768	
EXAMINER		DATE CONSIDERED	

*A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5213	Application No. 10/601,242
		Applicant Phillip Dan Cook, et al.	
		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	21	Matteucci, "Hybridization Properties of a Deoxyoligonucleotide Containing Four Formacetal Linkages", <i>Nucleosides & Nucleotides</i> , 1991 , 10, 231-234	
	22	Matteucci, "Deoxyoligonucleotide Analogs Based on Formacetal Linkages", <i>Tetrahedron Letters</i> , 1990 , 31 2385-2388	
	23	Mertes and Coats, "Synthesis of Carbonate Analogs of Dinucleosides. 3'-Thymidinyl 5'-Thymidinyl Carbonate, 3'-Thymidinyl 5'-(5-Fluoro-2'-deoxyuridinyl) Carbonate, and 3'-(5-Fluoro-2'-deoxyuridinyl) 5'-Thymidinyl Carbonate", <i>J. Med. Chem.</i> , 1969 , 12, 154-157	
	24	Miller et al., "Effects of a Trinucleotide Ethyl Phosphotriester, G ^m p(Et)G ^m p(Et)U, on Mammalian Cells in Culture", <i>Biochemistry</i> , 1977 , 16, 1988-1996	
*	25	Miller et. al., Chapter 6, Synthesis of oligo-2'-deoxyribonucleoside methylphosphonates, page 137, <i>Oligonucleotides and Analogs, A Practical Approach</i> , Eckstein, F., Ed.; The Practical Approach Series, IRL Press, New York, 1991	
	26	Miller and Ts'o, "A New Approach to Chemotherapy Based on Molecular Biology and Nucleic Acid Chemistry: Matagen (Masking Tape for Gene Expression)", <i>Anti-Cancer Drug Design</i> , 1987 , 2, 117-128	
	27	Miller et al., "Oligonucleotide Inhibitors of Gene Expression in Living Cells: New Opportunities in Drug Design", <i>Annual Reports in Medicinal Chemistry</i> , 1988 , Ch. 30, 295-304	
	28	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression", <i>J. Bio. Chem.</i> , 1993 , 208, 14514-14522	
	29	Musicki and Widlanski, "Synthesis of Nucleoside Sulfonates and Sulfones", <i>Tetrahedron Letters</i> , 1991 , 32, 1267-1270	
	30	Musicki and Widlanski, "Synthesis of Carbohydrate Sulfonates and Sulfonate Esters", <i>J. of Organic Chemistry</i> , 1990 , 55, 4231-4233	
EXAMINER		DATE CONSIDERED	

* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5213	Application No. 10/601,242
		Applicant Phillip Dan Cook, et al.	
		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	31	Ogilvie and Cormier, "Synthesis of a Thymidine Dinucleotide Analogue Containing an Internucleotide Silyl Linkage", <i>Tetra. Lett.</i> , 1985 , 26, 4159-4162	
	32	Perbost et al., "Sugar Modified Oligonucleotides I. Carbo-Oligodeoxynucleotides as Potential Antisense Agents", <i>Biochem. Biophys. Res. Commun.</i> , 1989 , 165, 742-747	
	33	Petersen et al., "Chemical Synthesis of Dimer Ribonucleotides Containing Internucleotidic Phosphoradithioate Linkages", <i>Tetra. Lett.</i> , 1990 , 31, 911-914	
	34	Sagi et al., "Biochemical Properties of Oligo[(+)-Carbocyclic-Thymidylates] and Their Complexes", <i>Nucl. Acids Res.</i> , 1990 , 18, 2133-2140	
	35	Saison-Behmoaras et al., "Short Modified Antisense Oligonucleotides Directed against Ha-ras Point Mutation Induce Selective Cleavage of the mRNA and Inhibit T24 Cells Proliferation", <i>EMBO J.</i> , 1991 , 10, 1111-1118	
	36	Schneider et al., "Oligonucleotides Containing Flexible Nucleoside Analogues", <i>J. Am. Chem. Soc.</i> , 1990 , 112, 453-455	
	37	Schneider, K. Christian and Benner, Steven A., "Building Blocks for Oligonucleotide Analogs with Dimethylene-Sulfide, Sulfoxide, and Sulfone Groups Replacing Phosphodiester Linkages" <i>Tetra Lett.</i> , 1990 , 31, 335-338	
	38	Secrist, et. al., "Synthesis and Biological Activity of 4'-Thionucleosides" <i>Tenth International Roundtable: Nucleosides, Nucleotides and Their Biological Evaluation</i> , September 16-20, 1992, Abstracts of Papers, Abstract 21	
	39	Stawinski Jacek and Thelin Mats, <i>Tenth International Roundtable: Nucleosides, Nucleotides and Their Biological Evaluation</i> , September 78, 1992, Abstracts of Papers, Abstract 80	
	40	Vasseur et al., "Oligonucleosides: Synthesis of Novel Methylhydroxylamine-Linked Nucleoside Dimer and Its Incorporation into Antisense Sequences", <i>J. Am. Chem. Soc.</i> , 1992 114, 4006-4007	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5213	Application No. 10/601,242
		Applicant Phillip Dan Cook, et al.	
		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	41	Atkinson and Smith, "Solid-Phase Synthesis of Oligodeoxyribonucleotides by the Phosphite-triester Method", <i>Oligonucleotide Synthesis a practical approach</i> , Ch. 3, 35-81, 1991	
	42	Berkowitz et al., ASynthesis of 1,2-Dihydro-1-(2deoxy- β -D-Erythro-pentafulanosyl)-2-Oxopyrazine 4-oxide", <i>J. Med. Chem.</i> , 1973, 16(2), 183-184	
	43	Biggadike et al., "Short Convergent Route to Homochiral Carbocyclic 2'-Deoxynucleosides and Carbocyclic Ribonucleosides", <i>J. Chem Soc., Chem Commun.</i> , 1987, 1083-1084	
	44	Block et al., <i>Gene</i> , 1988, 72, 349-360	
	45	Veeneman et al., "Synthesis of Oligodeoxynucleotides Containing Thymidines Linked Via an Internucleosidic-(3'-5')-Methylene Bond", <i>Recueil des Travaux Chimiques des Pays-Bas</i> , 1990 109, 7-8, 449-451	
	46	Agris et al., "Inhibition of Vesicular Stomatitis Virus Protein Synthesis and Infection by Sequence-Specific Oligodeoxyribonucleoside Methylphosphonates", <i>Biochem.</i> , 1986, 25(20), 6268-6275	
	47	Brill et al., "Synthesis of Oligodeoxynucleoside Phosphorodithioates via Thioamidites", <i>J. Am. Chem. Soc.</i> , 1989, 111, 2321-2322	
	48	Castle and Seese, "Imidazo[4,5-d]pyridazines I. Synthesis of 4,7-Disubstituted Derivatives", <i>J. Org. Chem.</i> , 1958, 23, 1534-1538	
	49	Cazenave et al., "Enzymatic Amplification of Translation Inhibition of Rabbit β -globin mRNA Mediated by Anti-Messenger Oligodeoxynucleotides Covalently Linked to Intercalating Agents", <i>Nucleic Acids Research</i> , 1987, 15(12), 4717-4736	
	50	Constant et al., "Heterodimeric Molecules Including Nucleic Acid Bases and 9-Aminoacridine. Spectroscopic Studies, Conformations, and Interactions with DNA", <i>Biochemistry</i> , 1988, 27, 3997-4003	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5213	Application No. 10/601,242
		Applicant Phillip Dan Cook, et al.	
		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	51	Dreyer and Dervan, "Sequence-Specific Cleavage of Single-Stranded DNA: Oligodeoxynucleotide-EDTA-Fe(II)", <i>Proc. Natl. Acad. Sci. USA</i> , 1985 , 82, 968-972	
	52	Freskos, J.N., "Synthesis of 2'-Deoxypyrimidine Nucleosides Via Copper (I) Iodide Catalysis", <i>Nucleosides & Nucleotides</i> , 1989 , 8(5&6), 1075-1076	
	53	Ikehara et al., <i>Nucl. Acids Res.</i> , 1977 , 4(12), 4249-4260	
	54	Inoue et al., "Sequence-dependent Hydrolysis of RNA Using Modified Oligonucleotide Splints and RNase H", <i>Febs. Ltrs.</i> , 1987 , 215, 327-330	
	55	Inoue et al., "Synthesis and Hybridization Studies on Two Complementary Nona(2'-O-Methyl)Ribonucleotides", <i>Nucl. Acids. Res.</i> , 1987 , 15, 6131-6148	
	56	Jarvi et al., "Synthesis and Biological Evaluation of Dideoxynucleosides Containing a Difluoromethylene Unit", <i>Nucleosides & Nucleotides</i> , 1989 , 8(5&6), 1111-1114	
	57	Jayaraman et al., "Selective Inhibition of Escherichia Coli Protein Synthesis and Growth by Nonionic Oligonucleotides Complementary to the 3' End of 16S rRNA", <i>Proc. Natl. Acad. Sci. USA</i> , 1981 , 78(3), 1537-1541	
	58	Jones, R.A., "Preparation of Protected Deoxyribonucleosides", from <i>Oligonucleotide Synthesis-A Practical Approach</i> , 1991 , Ch. 2, 23-34	
	59	Jones et al., "4-Substituted Nucleosides. 5. Hydroxymethylation of Nucleoside 5'-Aldehydes", <i>J. Org. Chem.</i> , 1979 , 44(8), 1309-1317	
	60	Kazimierczuk et al., "Synthesis of 2'-Deoxytubercidin, 2'-Deoxyadenosine, and Related 2'-Deoxynucleosides via A Novel Direct Stereospecific Sodium Salt Glycosylation Procedure", <i>J. Am. Chem. Soc.</i> , 1984 , 106, 6379-6382	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5213	Application No. 10/601,242
		Applicant Phillip Dan Cook, et al.	
		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	61	Le Doan et al., "Sequence-Targeted Chemical Modifications of Nucleic Acids by Complimentary Oligonucleotides Covalently Linked to Porphyrins", <i>Nucl. Acids Res.</i> , 1987 , 15(21), 8643-8659	
	62	Letsinger et al., "Effects of Pendant Groups at Phosphorus on Binding Properties of d-ApA Analogues", <i>Nucleic Acids Research</i> , 1986 , 14(8), 3487-3499	
	63	Matsukura et al., "Phosphorothioate Analogs of Oligodeoxynucleotides: Inhibitors of Replication and Cytopathic Effects of Human Immunodeficiency Virus", <i>Proc. Natl. Acad. Sci. USA</i> , 1987 , 84, 7706-7710	
	64	Meyer et al., "Efficient, Specific Cross-Linking and Cleavage of DNA by Stable, Synthetic Complementary Oligodeoxynucleotides", <i>J. Am. Chem. Soc.</i> , 1989 , 111, 8517-8519	
	65	Miller et al., "Biochemical and Biological of Nonionic Nucleic Acid Methylphosphonates", <i>Biochemistry</i> , 1981 , 20 1874-1880	
	66	Miller et al., "Nonionic Nucleic Acid Analogues. Synthesis and Characterization of Dideoxyribonucleoside Methylphosphonates", <i>Biochemistry</i> , 1979 , 18, 5134-5142	
	67	Miller et al., "Synthesis and Properties of Adenine and Thymine Nucleoside Alkyl Phosphotriesters, the Neutral Analogs of Dinucleoside Monophosphates", <i>J. Am. Chem. Soc.</i> , 1971 , 93(24), 6657-6664	
	68	Outten, R.A., "Synthetic 1-Methoxybenzo[d]naphtho[1,2-b]pyran-6-one C-Glycosides", <i>J. Org. Chem.</i> , 1987 , 52(22), 5064-5066	
	69	Revankar et al., "Synthesis and Antiviral/Antitumor Activities of Certain 3-Deazaguanine Nucleosides and Nucleotides", <i>J. Med. Chem.</i> , 1984 , 27, 1389-1396	
	70	Robins et al., "Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereoselective Conversion of Ribonucleosides to 2'-Deoxynucleosides", <i>J. Am. Chem. Soc.</i> , 1983 , 105, 4059-4065	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5213	Application No. 10/601,242
		Applicant Phillip Dan Cook, et al.	
		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	71	Roelen et al., "Synthesis of Nucleic Acid Methylphosphonothioates", <i>Nucleic Acids Research</i> , 1988 , 16(15), 7633-7645	
	72	Ruby and Abelson, "An Early Hierarchic Role of U1 Small Nuclear Ribonucleoprotein in Spliceosome Assembly", <i>Science</i> , 1988 , 242, 1028-1035	
	73	Sigman, D.S., "Nuclease Activity of 1,10-Phenanthroline-Copper Ion", <i>Acc. Chem. Res.</i> , 1986 , 19, 180-186	
	74	Smith et al., "Antiviral Effect of an Oligo(nucleoside Methylphosphonate) Complementary to the Splice Junction of Herpes Simplex Virus Type 1 Immediate Early pre-mRNAs 4 and 5", <i>Proc. Natl. Acad. Sci. USA</i> , 1986 , 83, 2787-2791	
	75	Stein, C.A., "Physiochemical Properties of Phosphorothioate Oligodeoxynucleotides", <i>Nucleic Acids Research</i> , 1988 , 16(8), 3209-3221	
	76	Suciu and Lerner, "Synthesis of 9-(2,5-dideoxy- β -D-glycero-pent-4-enofuranosyl)adenine", <i>Carbohydrate Research</i> , 1975 , 44, 112-115	
	77	Tidd et al., "Evaluation of N-ras Oncogene Anti-Sense, Sense and Nonsense Sequence Methylphosphonate Oligonucleotide Analogues", <i>Anti-Cancer Drug Design</i> , 1988 , 3, 117-127	
	78	van der Krol, "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences", <i>BioTechniques</i> , 1988 , 6(10), 958-974	
	79	Walder and Walder, "Role of RNase H in Hybrid-Arrested Translation by Antisense Oligonucleotides", <i>Proc. Natl. Acad. Sci. USA</i> , 1988 , 85, 5011-5015	
	80	Yeung et al., "Photoreactivities and Thermal Properties of Psoralen Cross-Links", <i>Biochemistry</i> , 1988 , 27, 3204-3210	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5213	Application No. 10/601,242
		Applicant Phillip Dan Cook, et al.	
		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	81	Zon, G., "Synthesis of Backbone-Modified DNA Analogues for Biological Applications", <i>J. Protein Chem.</i> , 1987 , 6(2), 131-145	
	82	Inoue et al., "Synthesis and Properties of Novel Nucleic Acid Probes", <i>Nucl. Acids Res., Symposium Series</i> , 1985 , 16, 165-168	
	83	Szemzo et. al., "First Synthesis of Carbocyclic Oligothymidylates", <i>Tetra. Lett.</i> , 1990 , 31, 1463-1466	
	84	Uhlmann et al., AAntisense oligonucleotides: A new therapeutic principle@, <i>Chem. Reviews</i> , 1990 , 90(4), 544-584	
	85	Antisense >97: A roundtable on the state of the industry, <i>Nature Biotech.</i> , 1997 , 15, 519-524	
	86	Fujimori et al., AEnantio-DNA recognizes complementary RNA but not complementary DNA@, <i>J. Am. Chem. Soc.</i> , 1990 , 112(20), 7436-7438	
	87	Gewirtz et al., AFacilitating oligonucleotide delivery: Helping antisense deliver on its promise@, <i>Proc. Natl. Acad. Sci. USA</i> , 1996 , 93, 3161-3163	
	88	Gura, AAntisense has growing pains@, <i>Science</i> , 1995 , 270, 575-577	
	89	Milligan et al., ACurrent concepts in antisense drug design@, <i>J. Med. Chem.</i> , 1993 , 36(14), 1923-1937	
	90	Stull et al., Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects@, <i>Pharm. Res.</i> , 1995 , 12(4), 465-483	
EXAMINER		DATE CONSIDERED	




Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5213	Application No. 10/601,242
		Applicant Phillip Dan Cook, et al.	
		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	91	deBufalo, et al., AEffect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo,@ <i>British J. Cancer</i> , August 1996, 3, 387-393	
	92	Kitajima, et al., AAblation of transplanted HTLV tax tumors in mice by antisense inhibition of NF-kB, <i>Science</i> , December 1992, 258, 1792-1796	
	93	Leonetti, et al., AAntitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice,@ <i>J. National Cancer Institute</i> , April 1996, 88(7), 419-429	
	94	Monia, et al., AAntitumor activity of a phosphorothioate antisense oligodeoxynucleotides targeted against C-raf kinase, <i>Nature Medicine</i> , June 1996, 2(6), 668-674	
	95	Neurath, et al., ALocal administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kB abrogates established expermantal colitis in mice, <i>Nature Medicine</i> , September 1996, 2(9), 997-1002	
	96	Oberbauer, et al., AIn vivo suppression of the renal Na+/Pi cotransporter by antisense oligonucleotides, <i>Physiology</i> , May 1996, 93, 4903-4906	
	97	Offensperger, et al., AIn vivo inhibition of duck hepatitis B viris replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides,@ <i>EMBO J.</i> , 1993, 12(3), 1257-1262	
	98	Simons, et al., AAntisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo,@ <i>Nature</i> , September 1992, 359, 67-70	
	99	Sun, et al., AEffect of phosphorothioated neuropeptide Y Y1-receptor antisense oligodeoxynucleotide in conscious in conscious rates and human vessels, <i>British J. Pharmacology</i> , 1996, 118, 131-136	
	100	Jen, et al., ASuppression of gene expression by targeted disruption of messenger RNA: available options and current strategies,@ <i>Stem Cells</i> , 2000, 18, 307-319	
EXAMINER		DATE CONSIDERED	




Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5213	Application No. 10/601,242
		Applicant Phillip Dan Cook, et al.	
		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	101	Rojanasakul, Y., AAntisense oligonucleotide therapeutics: drug delivery and targeting,@ <i>Adv. Drug Delivery Rev.</i> , 1996 , 18, 115-131	
	102	Monia, et al., ASequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted of human C-raf kinase supports an antisense mechanism of action in vivo,@ <i>Pharmacology</i> , December 1996 , 15481-15484	
	103	Offensperger, et al., AAntisense therapy of hepatitis B virus infection, <i>Antisense Therapeutics</i> , 1996 , 143-158	
	104	Nielsen, P.E., ASequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide,@ <i>Science</i> , December 6, 1991 , 5037, XP 000405940, 1497-1500	
	105	Agrawal, S., et al., "Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides," <i>Proc. Nat'l Acad. Sci.</i> , February 1990 , 87, 1401-1405	
	106	Boado, R.J., et al., "Complete inactivation of target mRNA by biotinylated antisense oligodeoxynucleotide-avidin conjugates," <i>Bioconjugate Chemistry</i> , 1994 , 5, 406-410	
	107	Bordier, B., et al., "Sequence-specific inhibition of human immunodeficiency virus (HIV) reverse transcription by antisense oligonucleotides: comparative study in cell-free assays and in HIV infected cells," <i>Proc. Nat'l Sci. U.S.A.</i> , September 1995 , 92, 9383-9387	
	108	Chiang, M., et al., "Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms," <i>J. Biological Chemistry</i> , September 25, 1991 , 18162-18171	
	109	Dean, N.M., et al., "Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters," <i>J. Biological Chemistry</i> , June 10, 1994 , 269, 16416-16424	
	110	Frank, P., et al., "Purification and characterization of human ribonuclease HII," <i>Nucleic Acids Res.</i> , 1994 , 22, 5247-5254	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. ISIS-5213	Application No. 10/601,242
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Phillip Dan Cook, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	111	Furdon, P.J., et al., "RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds," <i>Nucleic Acid Res.</i> , November 22, 1989, 17, 9193-9204	
	112	Giles, R.V., et al., "Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides," <i>Anticancer Drug Design</i> , 1992, 7, 37-48	
	113	Giles, R.V., et al., "Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures," <i>Nucleic Acids Res.</i> , 1992, 20, 763-770	
	114	Godard, G., et al., "Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles," <i>European J. Biochemistry</i> , 1995, 232, 404-410	
	115	ISIS Pharmaceuticals, Inc. v. Sequitur, Inc. United States District Court Southern District of California, Case No. 01 CV 1223 B (JFS), "Sequitur's Preliminary Invalidity Contentions for U.S. Patent No. 6,326,199," Richard J. Warburg, May 17, 2002, 1-43	
	116	Lee, C., et al., "Antisense gene suppression against human ICAM-1, ELAM-1, and VCAM-1 in cultured human umbilical vein endothelial cells," <i>Shock</i> , July 1995, 4, 1-10	
	117	Woolf, T.M., et al., "The stability, toxicity, and effectiveness of unmodified and phosphorothioate, oligodeoxynucleotides in xenopus oocytes and embryos," <i>Nucleic Acids Res.</i> , 1990, 18, 1763	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISIS-5213	Application No. 10/601,242
	Applicant Phillip Dan Cook, et al.	
	Filing Date June 20, 2003	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	



U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	118	5,149,797	09/22/92	Pederson, et al.	536	27
	119	5,013,830	05/07/91	Ohtsuka, et al.	536	27
	120	5,134,066	07/28/92	Rogers, et al.	435	91
	121	4,908,307	03/13/90	Rodland, et al.	435	6
	122	5,034,506	07/23/91	Summerton, et al.	528	391
	123	5,256,775	06/05/90	Froehler	536	25.6
	124	5,403,711	07/06/93	Walder, et al.	435	6
	125	4,867,187	10/24/89	Duck	435	6
	126	5,220,007	06/15/93	Pederson et al.	536	23.1
	127	5,366,878	11/22/94	Pederson et al.	435	91.3
	128	5,466,786	11/14/95	Buhr et al.	536	26.26
	129	5,658,731	08/19/97	Sproat et al.	435	6
	130	5,962,425	10/05/99	Walder et al.	514	44
	131	5,623,065	04/22/97	Cook et al.	536	23.1
	132	5,652,355	07/1997	Metlev, et al.	536	24.5
	133	5,856,455	01/05/99	Cook	536	23.1
	134	5,955,589	09/1999	Cook, et al.	536	23.1
	135	6,146,829	11/2000	Cook, et al.	435	6

EXAMINER

DATE CONSIDERED

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISIS-5213	Application No. 10/601,242
	Applicant Phillip Dan Cook, et al.	
	Filing Date June 20, 2003	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	136	US 6,326,199 B1	12/04/01	Cook, et al.	435	375
	137	5,856,455	01/99	Cook	536	23.1
	138	5,459,255	10/95	Cook, et al.	536	27.13
	139	5,525,468	06/11/96	McSwiggen	435	6

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	140	39 15 462	09/06/90	Germany		
	141	0 339 330	11/28/90	EPO		
	142	2,017,369	11/24/90	Canada		
	143	WO 90/15814	06/20/90	PCT		
	144	WO 91/06556	10/24/90	PCT		
	145	WO 91/15499	04/08/91	PCT		
	146	WO 92/07065	09/24/94	PCT		
	147	41 10 085	10/01/92	Germany		
	148	WO 91/12323	08/22/91	PCT		
	149	WO 94/02498	02/03/94	PCT		

EXAMINER

DATE CONSIDERED

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.
ISIS-5213

Application No.
10/601,242

Applicant
Phillip Dan Cook, et al.

Filing Date
June 20, 2003

Group
Not Yet Assigned

Confirmation No.
Not Yet Assigned

FOREIGN PATENT DOCUMENTS

Examiner
Initial

Translation**YES****NO****Document No.****Date****Country****150**

365627B1

03/13/89

EPO

151

WO 89/05358

06/15/89

PCT

152

0 260 032

08/27/87

EPO

153

30240795

1991

Japan

154

0 339 842

04/13/89

EPO

155

WO 93/13121 A1

07/1993

PCT

156

WO 86/05518

09/25/86

PCT

157

WO 86/05519

09/25/86

PCT

158

WO 92/20702

11/26/92

PCT

159

WO 92/20703

11/26/92

PCT

160

WO 93/12129

06/24/93

PCT

EXAMINER**DATE CONSIDERED**